Urothelial cancer is another typical HER-2-overexpressing cancer, and its response to disitamab has also been evaluated [107] in a phase II study (NCT04264936) on patients with HER-2 locally advanced or metastatic urothelial cancer refractory to classical therapies, which showed good overall survival and a promising efficacy with a manageable safety profile [108]. The gene discussed is ERBB2; the disease is cancer.